Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.
Natural self-reactive antibodies in the peripheral blood may play a considerable role in the control of potentially toxic proteins that may otherwise accumulate in the aging brain. The significance of serum antibodies reactive against α-synuclein is not well known. We explored serum IgG levels to mo...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5e789229a17a412f996ecb93e4029b96 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5e789229a17a412f996ecb93e4029b96 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5e789229a17a412f996ecb93e4029b962021-11-18T07:43:36ZAltered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.1932-620310.1371/journal.pone.0064649https://doaj.org/article/5e789229a17a412f996ecb93e4029b962013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23741358/?tool=EBIhttps://doaj.org/toc/1932-6203Natural self-reactive antibodies in the peripheral blood may play a considerable role in the control of potentially toxic proteins that may otherwise accumulate in the aging brain. The significance of serum antibodies reactive against α-synuclein is not well known. We explored serum IgG levels to monomeric α-synuclein in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) with a novel and validated highly sensitive ELISA assay. Antibody levels revealed stark differences in patients compared to healthy subjects and were dependent on diagnosis, disease duration and age. Anti-α-synuclein IgG levels were increased in both patient groups, but in early DLB to a much greater extent than in AD. Increased antibody levels were most evident in younger patients, while with advanced age relatively low levels were observed, similar to healthy individuals, exhibiting stable antibody levels independent of age. Our data show the presence of differentially altered IgG levels against α-synuclein in DLB and AD, which may relate to a disturbed α-synuclein homeostasis triggered by the disease process. These observations may foster the development of novel, possibly preclinical biomarkers and immunotherapeutic strategies that target α-synuclein in neurodegenerative disease.Niklas K U KoehlerElke StranskyMona ShingSusanne GaertnerMirjam MeyerBrigitte SchreitmüllerThomas LeyheChristoph LaskeWalter MaetzlerPhillipp KahleMaria S CelejThomas M JovinAndreas J FallgatterAnil BatraGerhard BuchkremerKlaus SchottElke Richartz-SalzburgerPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e64649 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Niklas K U Koehler Elke Stransky Mona Shing Susanne Gaertner Mirjam Meyer Brigitte Schreitmüller Thomas Leyhe Christoph Laske Walter Maetzler Phillipp Kahle Maria S Celej Thomas M Jovin Andreas J Fallgatter Anil Batra Gerhard Buchkremer Klaus Schott Elke Richartz-Salzburger Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. |
| description |
Natural self-reactive antibodies in the peripheral blood may play a considerable role in the control of potentially toxic proteins that may otherwise accumulate in the aging brain. The significance of serum antibodies reactive against α-synuclein is not well known. We explored serum IgG levels to monomeric α-synuclein in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) with a novel and validated highly sensitive ELISA assay. Antibody levels revealed stark differences in patients compared to healthy subjects and were dependent on diagnosis, disease duration and age. Anti-α-synuclein IgG levels were increased in both patient groups, but in early DLB to a much greater extent than in AD. Increased antibody levels were most evident in younger patients, while with advanced age relatively low levels were observed, similar to healthy individuals, exhibiting stable antibody levels independent of age. Our data show the presence of differentially altered IgG levels against α-synuclein in DLB and AD, which may relate to a disturbed α-synuclein homeostasis triggered by the disease process. These observations may foster the development of novel, possibly preclinical biomarkers and immunotherapeutic strategies that target α-synuclein in neurodegenerative disease. |
| format |
article |
| author |
Niklas K U Koehler Elke Stransky Mona Shing Susanne Gaertner Mirjam Meyer Brigitte Schreitmüller Thomas Leyhe Christoph Laske Walter Maetzler Phillipp Kahle Maria S Celej Thomas M Jovin Andreas J Fallgatter Anil Batra Gerhard Buchkremer Klaus Schott Elke Richartz-Salzburger |
| author_facet |
Niklas K U Koehler Elke Stransky Mona Shing Susanne Gaertner Mirjam Meyer Brigitte Schreitmüller Thomas Leyhe Christoph Laske Walter Maetzler Phillipp Kahle Maria S Celej Thomas M Jovin Andreas J Fallgatter Anil Batra Gerhard Buchkremer Klaus Schott Elke Richartz-Salzburger |
| author_sort |
Niklas K U Koehler |
| title |
Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. |
| title_short |
Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. |
| title_full |
Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. |
| title_fullStr |
Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. |
| title_full_unstemmed |
Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. |
| title_sort |
altered serum igg levels to α-synuclein in dementia with lewy bodies and alzheimer's disease. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/5e789229a17a412f996ecb93e4029b96 |
| work_keys_str_mv |
AT niklaskukoehler alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT elkestransky alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT monashing alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT susannegaertner alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT mirjammeyer alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT brigitteschreitmuller alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT thomasleyhe alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT christophlaske alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT waltermaetzler alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT phillippkahle alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT mariascelej alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT thomasmjovin alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT andreasjfallgatter alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT anilbatra alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT gerhardbuchkremer alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT klausschott alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease AT elkerichartzsalzburger alteredserumigglevelstoasynucleinindementiawithlewybodiesandalzheimersdisease |
| _version_ |
1718423038858362880 |